Promestriene

DB12487InvestigationalSmall molecule

Promestriene is a synthetic estrogen applied topically for the treatment of vulvovaginal atrophic symptoms and to speed wound healing following vulvovaginal surgery or trauma (e.g. post-partum). Promestriene (3-propyl ethyl, 17B-methyl estradiol) has been used in trials studying the prevention of Hypospadias.

Chemical structure of Promestriene
Formula / weight
C22H32O2 · 328.496 g/mol (avg)

Resolves to

Compound
UNIIGXM4PER6WZCAS39219-28-8ChEMBLCHEMBL2105394ChEBI135402
Clinical / RWD
RxNorm34625ATCG03CA09
Structure
InChIKeyIUWKNLFTJBHTSD-AANPDWTMSA-NSMILES[H][C@@]12CC[C@H](OC)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(OCCC)C=C3
Targets
P03372ESR1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
421Drug interactionsStructured to mechanism, not free text
Sign in
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
17ContraindicationsEach with its own population and attribute set
Sign in
10Marketed productsAcross 2 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 13 drug categories
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Promestriene, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In